Genopsy Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Genopsy Co., Ltd. - overview
Established
2018
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2018 and based in Seoul, South Korea, Genopsy Co. , Ltd. operates as a biotechnology company that develops nanowrire technology and identifies tumor-derived cell-free DNA in cancer patients' body fluids. In June 2019, Genopsy Co.
, Ltd. raised KW 10 billion in series A funding from NewFlight. As of 2023, Cho Young-nam serves as the CEO of the company. The company offers its unique nanowire technology, which enables the selective capture and detection of tumor-derived cell-free DNA (cfDNA) from body fluids in cancer patients.
The non-PCR approach used by the firm isolates cfDNA from bodily fluids and detects DNA variations or mutations without the need for polymerase chain reaction (PCR) amplification for the diagnosis of cancer.
Current Investors
NewFlight
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.genopsybio.com
Verticals
Nanotechnology
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.